LOGIN  |  REGISTER
Astria Therapeutics

Quantum-Si to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 21, 2025 | Last Trade: US$2.27 0.27 -10.63

BRANFORD, Conn. / Jul 21, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the Canaccord Genuity 45th Annual Growth Conference taking place at the InterContinental Boston Hotel, August 12-14, 2025.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer will be taking one-on-one meetings throughout the day on Tuesday, August 12, 2025 and will participate in a fireside chat on the same day at 4:00 PM Eastern Time.

A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page